Adverse events: Paresthesias‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
Acetazolamide may leads to higher adverse events: Paresthesias‐ Follow‐ up: From arrival to 24 hours… compared with placebo (low certainty).
1 finding from 1 review
Side effects or other adverse events · participants at risk of high altitude illness
Acetazolamide may leads to higher adverse events: side effects‐ Follow‐ up: From arrival to 24 hours… compared with placebo (low certainty).
1 finding from 1 review
Side effects or other adverse events · participants at risk of high altitude illness
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Specific ‐ prolactin‐related Reported by… compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review
Adverse events: General ‐ serious Unclear how these events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: General ‐ serious Unclear how these events were… compared with ORAL ARIPIPRAZOLE (very low certainty).
1 finding from 1 review
Adverse events associated with the use of anticoagulants (e.g. bleeding) · people with sickle cell disease
Tinzaparin showed no clear difference in adverse events associated with the use of anticoagulants (e.g.… compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants with ≥ 1 serious adverse events ‐ not reported · adults with biliary sphincter of Oddi dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events Maximum · people with leptospirosis
It is very uncertain whether summary of findings table ‐ Antibiotics changes adverse events considered non‐serious (penicillin versus… compared with other antibiotics (very low certainty).
1 finding from 1 review
Serious adverse events with use of FMT for maintenance of remission in CD · Participants with Crohn's disease in remission
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
Non‐serious adverse events Timing of outcome assessment: end of treatment · patients with borderline personality disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (e.g. skin complaints) other than musculoskeletal injuries · healthy adults participating in recreational running
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (e.g. skin complaints) other than musculoskeletal injuries · healthy adults participating in recreational running
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (e.g. skin complaints) other than musculoskeletal injuries · military personnel
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (e.g. skin complaints) other than musculoskeletal injuries · healthy adults participating in recreational running
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major adverse events (eyelid ptosis, eyelid sensory disorder, strabismus) · glabellar lines
Summary of Findings Table ‐ AbobotulinumtoxinA 50U showed no clear difference in major adverse events (eyelid ptosis, eyelid sensory disorder,… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events attributable to treatment · infants with SMA and 2 SMN2 copies
Intrathecal injected nusinersen showed no clear difference in adverse events attributable to treatment Measured as adverse events… compared with sham procedure (moderate certainty).
1 finding from 1 review
Time to treatment failure due to adverse events All participants Range of · people with newly diagnosed epilepsy
Summary of findings: oxcarbazepine leads to lower time to treatment failure due to adverse events All participants… compared with phenytoin (primary outcomes) (high certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · people with Alzheimer's disease
Vitamin E (capsules 2000 IU/day in two divided doses) showed no clear difference in adverse events Number of participants reporting ≥ 1 serious adverse… compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Number of participants withdrawn due to adverse events (at 6 to 10 weeks) · Adults with ADHD
The intervention showed no clear difference in number of participants withdrawn due to adverse events (at 6 to 10… (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · women with PMS
1 finding from 1 review